利拉鲁肽对腹型肥胖2型糖尿病患者胰岛素抵抗、同型半胱氨酸影响观察

Observation of the effect of liraglutide on insulin resistance and homocysteine in patients with abdominal obesity and type 2 diabetes

目的:探究在临床治疗肥胖2型糖尿病患者的过程中,应用胰高血糖素样肽-1受体激动剂(GLP-1)的治疗效果,为糖尿病治疗奠定基础。方法:选择肥胖2型糖尿病患者随机抽取110例为研究对象,分为观察组和对照组,每组55例。两组均给予胰岛素泵强化降糖治疗,2周后,其中对照组给予一般降糖治疗,观察组加用胰高血糖素样肽-1受体激动剂。3个月后对比两组患者空腹血糖、糖化血红蛋白水平、空腹胰岛素水平、同型半胱氨酸、体重、胰岛β细胞功能指数等变化。结果:应用利拉鲁肽治疗3个月后的观察组患者的空腹血糖、糖化血红蛋白、空腹胰岛素水平、同型半胱氨酸以及胰岛β细胞功能指数均显著优于对照组,差异有统计学意义(P<0.05)。应用利拉鲁肽治疗3个月后的观察组患者的体重均显著低于对照组,差异有统计学意义(P<0.05)。结论:在临床治疗肥胖2型糖尿病患者的过程中,应用胰高血糖素样肽-1受体激动剂可明显改善胰岛素抵抗、降低同型半胱氨酸水平,且体重减轻,有利于血糖控制,具有较高的安全系数,值得广泛推广。

Objective To explore the therapeutic effect of glucagon-like peptide-1 receptor agonist(GLP-1)in the clinical treatment of obese patients with type 2 diabetes,and lay the foundation for the treatment of diabetes.Method 110 obese type 2 diabetes patients admitted to our hospital were randomly selected as the research objects and divided into observation group and control group,55 cases in each group,both groups were given insulin pumps Intensified hypoglycemic treatment.After 2 weeks,the control group was given general hypoglycemic treatment,and the observation group was given a glucagon-like peptide-1 receptor agonist.Three months later,the changes in fasting blood glucose,glycosylated hemoglobin levels,fasting insulin levels,homocysteine,body weight,and pancreaticβ-cell function index were compared between the two groups.Results After 3 months of treatment with liraglutide,the fasting blood glucose,glycosylated hemoglobin,fasting insulin levels,homocysteine and isletβ-cell function index of the observation group were significantly better than those of the control group,and the difference was statistically significant(P<0.05).After 3 months of treatment with liraglutide,the weight of the observation group was significantly lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion In the process of clinical treatment of obese patients with type 2 diabetes,the application of glucagon-like peptide-1 receptor agonists can significantly improve insulin resistance,reduce homocysteine levels,and lose weight,which is beneficial to blood sugar control.It has a high safety factor and is worthy of widespread promotion.